| Literature DB >> 34950795 |
Masatsugu Nozoe1, Shinki Nishioka2, Keiji Oi1, Nobuhiro Suematsu1, Toru Kubota1.
Abstract
Background: The presence of a calcified nodule (CN) is associated with unfavorable clinical outcomes after percutaneous coronary intervention (PCI). This study clarified the optimal management of CNs by reassessing the PCI strategy in association with patient background characteristics and clinical outcomes. Methods andEntities:
Keywords: Calcified nodule; Hemodialysis; Percutaneous coronary intervention; Right coronary artery; Rotational atherectomy
Year: 2021 PMID: 34950795 PMCID: PMC8651471 DOI: 10.1253/circrep.CR-21-0129
Source DB: PubMed Journal: Circ Rep ISSN: 2434-0790
Clinical Characteristics of 167 Patients With Calcified Nodules
| Overall | ACS | In-stent restenosis | |||||
|---|---|---|---|---|---|---|---|
| − | + | P value | − | + | P value | ||
| No. patients | 167 | 74 | 93 | 134 | 33 | ||
| Age (years) | 73.1±10.2 | 72.0±9.5 | 73.9±10.7 | 0.235 | 73.2±10.4 | 72.6±9.3 | 0.788 |
| Male sex | 120 (71.9) | 57 (77.0) | 63 (67.7) | 0.226 | 93 (69.4) | 27 (81.8) | 0.197 |
| Hypertension | 141 (84.4) | 63 (85.1) | 78 (83.9) | 1 | 112 (83.6) | 29 (87.9) | 0.789 |
| Diabetes | 89 (53.3) | 44 (59.5) | 45 (48.4) | 0.164 | 68 (50.7) | 21 (63.6) | 0.243 |
| Dyslipidemia | 102 (61.1) | 50 (67.6) | 52 (55.9) | 0.151 | 85 (63.4) | 17 (51.5) | 0.235 |
| Hemodialysis | 55 (32.9) | 22 (29.7) | 33 (35.5) | 0.508 | 41 (30.6) | 14 (42.4) | 0.218 |
| Prior PCI | 84 (50.3) | 45 (60.8) | 39 (41.9) | 0.019 | 51 (38.1) | 33 (100.0) | <0.001 |
| Prior CABG | 15 (9.0) | 7 (9.5) | 8 (8.6) | 1 | 9 (6.7) | 6 (18.2) | 0.081 |
| Lesion location (RCA/LCA/SVG) | 104/62/1 | 46/27/1 | 58/35/0 | 0.732 | 74/59/1 | 30/3/0 | <0.001 |
| Multivessel disease | 133 (79.6) | 59 (79.7) | 74 (79.6) | 1 | 105 (78.4) | 28 (84.8) | 0.478 |
| ACS | 93 (55.7) | 0 (0.0) | 93 (100.0) | <0.001 | 78 (58.2) | 15 (45.5) | 0.241 |
| In-stent restenosis | 33 (19.8) | 18 (24.3) | 15 (16.1) | 0.241 | 0 (0.0) | 33 (100.0) | <0.001 |
Unless indicated otherwise, data are given as the mean±SD or n (%). ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; LCA, left coronary artery; PCI, percutaneous coronary intervention; RCA, right coronary artery; SVG, saphenous vein graft.
Figure 1.Survival curves (solid lines) for freedom from (A) major adverse cardiovascular events (MACEs), (B) all-cause death, and (C) target lesion revascularization (TLR) with 95% confidence intervals (dashed lines).
Results of Univariate and Multivariate Analyses of Factors Affecting All-Cause Death- and TLR-Free Survival in 167 Patients With Calcified Nodules
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Patient age | 0.971 | 0.949–0.994 | 0.013 | |||
| Male sex | 2.574 | 1.350–4.907 | 0.004 | 2.239 | 1.155–4.341 | 0.017 |
| Diabetes | 2.001 | 1.221–3.281 | 0.006 | |||
| Hemodialysis | 3.930 | 2.438–6.336 | 0.000 | 3.272 | 2.000–5.351 | 0.000 |
| RCA location | 1.457 | 0.867–2.449 | 0.155 | 1.849 | 1.101–3.106 | 0.020 |
| ACS | 1.542 | 0.950–2.504 | 0.080 | 2.080 | 1.245–3.475 | 0.005 |
| In-stent restenosis | 1.405 | 0.823–2.410 | 0.212 | |||
| Patient age | 0.986 | 0.947–1.026 | 0.485 | |||
| Male sex | 3.178 | 0.946–10.67 | 0.614 | |||
| Diabetes | 3.846 | 1.434–10.31 | 0.007 | 3.187 | 1.152–8.821 | 0.026 |
| Hemodialysis | 7.807 | 3.192–19.09 | 0.000 | 6.766 | 2.683–17.06 | 0.000 |
| RCA location | 0.596 | 0.268–1.328 | 0.205 | |||
| ACS | 1.877 | 0.798–4.414 | 0.149 | 2.494 | 1.015–6.129 | 0.046 |
| In-stent restenosis | 0.577 | 0.172–1.935 | 0.373 | |||
| Patient age | 0.964 | 0.937–0.991 | 0.010 | |||
| Male sex | 2.344 | 1.091–5.035 | 0.029 | |||
| Diabetes | 1.508 | 0.838–2.715 | 0.171 | |||
| Hemodialysis | 2.825 | 1.563–5.106 | 0.001 | 3.149 | 1.739–5.701 | 0.000 |
| RCA location | 2.738 | 1.277–5.872 | 0.010 | 3.093 | 1.437–6.655 | 0.004 |
| ACS | 1.398 | 0.775–2.525 | 0.266 | |||
| In-stent restenosis | 1.978 | 1.066–3.668 | 0.031 | |||
ACS, acute coronary syndrome; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event; RCA, right coronary artery; TLR, target lesion revascularization.
Figure 2.Survival curves for freedom from (A) major adverse cardiovascular events (MACEs), (B) all-cause death, and (C) target lesion revascularization (TLR) stratified by hemodialysis (HD) and right coronary artery (RCA) location.
Clinical Characteristics of 91 Patients With De Novo Calcified Nodules
| Overall | Restenosis | |||
|---|---|---|---|---|
| No | Yes | P value | ||
| No. patients | 91 | 62 | 29 | |
| Age (years) | 74.1±9.7 | 75.5±9.6 | 71.1±9.5 | 0.044 |
| Male sex | 63 (69.2) | 39 (62.9) | 24 (82.8) | 0.087 |
| Hypertension | 78 (85.7) | 53 (85.5) | 25 (86.2) | 1 |
| Diabetes | 42 (46.2) | 23 (37.1) | 19 (65.5) | 0.014 |
| Dyslipidemia | 64 (70.3) | 47 (75.8) | 17 (58.6) | 0.139 |
| Hemodialysis | 23 (25.3) | 12 (19.4) | 11 (37.9) | 0.072 |
| Prior PCI | 38 (41.8) | 22 (35.5) | 16 (55.2) | 0.11 |
| Prior CABG | 4 (4.4) | 4 (6.5) | 0 (0.0) | 0.302 |
| Lesion location (RCA/LMT-LAD/LCX) | 53/34/4 | 31/28/3 | 22/6/1 | 0.048 |
| Multivessel disease | 72 (79.1) | 49 (79.0) | 23 (79.3) | 1 |
| ACS | 49 (53.8) | 33 (53.2) | 16 (55.2) | 1 |
| Lesion characteristics | ||||
| ≥99% stenosis | 38 (41.8) | 21 (33.9) | 17 (58.6) | 0.039 |
| Tortuous | 53 (58.2) | 31 (50.0) | 22 (75.9) | 0.024 |
| Mild/moderate/severe calcification (n) | 8/23/60 | 7/18/37 | 1/5/23 | 0.217 |
| Treatment strategy | ||||
| Rotational atherectomy | 52 (57.1) | 41 (66.1) | 11 (37.9) | 0.014 |
| Scoring balloon | 37 (40.7) | 25 (40.3) | 12 (41.4) | 1 |
| Drug-eluting stent | 73 (80.2) | 47 (75.8) | 26 (89.7) | 0.162 |
| Drug-coated balloon | 12 (13.2) | 10 (16.1) | 2 (6.9) | 0.325 |
| ELCA | 2 (2.2) | 1 (1.6) | 1 (3.4) | 0.538 |
Unless indicated otherwise, data are given as the mean±SD or n (%). ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; ELCA, excimer laser coronary angioplasty; LAD, left anterior descending artery; LCX, left circumflex artery; LMT, left main trunk; PCI, percutaneous coronary intervention; RCA, right coronary artery.
Results of a Multivariate Analysis Concerning the Association With Restenosis in 91 De Novo Calcified Nodules
| Factor | OR | 95% CI | P value |
|---|---|---|---|
| Intercept | 0.133 | 0.033–0.528 | 0.004 |
| Hemodialysis | 3.520 | 1.000–12.40 | 0.049 |
| Diabetes | 3.330 | 1.170–9.490 | 0.024 |
| Right coronary artery | 4.290 | 1.240–14.90 | 0.022 |
| Rotational atherectomy | 0.291 | 0.103–0.823 | 0.020 |
CI, confidence interval; OR, odds ratio.
Clinical Characteristics of 73 Patients With Stent Implantation
| Overall | Restenosis | |||
|---|---|---|---|---|
| No | Yes | P value | ||
| No. patients | 73 | 47 | 26 | |
| Age (years) | 73.7±10.1 | 75.2±10.2 | 71.1±9.5 | 0.101 |
| Male sex | 49 (67.1) | 27 (57.4) | 22 (84.6) | 0.021 |
| Hypertension | 63 (86.3) | 41 (87.2) | 22 (84.6) | 0.737 |
| Diabetes | 32 (43.8) | 16 (34.0) | 16 (61.5) | 0.029 |
| Dyslipidemia | 54 (74.0) | 39 (83.0) | 15 (57.7) | 0.026 |
| Hemodialysis | 18 (24.7) | 8 (17.0) | 10 (38.5) | 0.052 |
| Prior PCI | 30 (41.1) | 15 (31.9) | 15 (57.7) | 0.047 |
| Prior CABG | 1 (1.4) | 1 (2.1) | 0 (0.0) | 1 |
| Lesion location (RCA/LMT-LAD/LCX) | 43/27/3 | 23/22/2 | 20/5/1 | 0.038 |
| Multivessel disease | 59 (80.8) | 37 (78.7) | 22 (84.6) | 0.758 |
| ACS | 37 (50.7) | 22 (46.8) | 15 (57.7) | 0.465 |
| Lesion characteristics | ||||
| ≥99% stenosis | 30 (41.1) | 16 (34.0) | 14 (53.8) | 0.137 |
| Tortuous | 45 (61.6) | 26 (55.3) | 19 (73.1) | 0.209 |
| Mild/moderate/severe calcification (n) | 6/18/49 | 6/14/27 | 0/4/22 | 0.042 |
| Rotational atherectomy | 35 (47.9) | 26 (55.3) | 9 (34.6) | 0.142 |
| Drug eluting stent | ||||
| Stent size (mm) | 3.14±0.37 | 3.13±0.38 | 3.16±0.38 | 0.742 |
| Stent length (mm) | 40.2±18.9 | 40.9±18.6 | 39.0±19.8 | 0.688 |
| RLA (mm2) | 7.41±2.73 | 7.32±2.70 | 7.58±2.85 | 0.706 |
| MSA (mm2) | 6.46±2.37 | 6.30±2.24 | 6.77±2.65 | 0.448 |
| MSA/RLA | 0.88±0.13 | 0.88±0.13 | 0.87±0.13 | 0.855 |
| Stent eccentricity index | 0.78±0.10 | 0.79±0.10 | 0.75±0.10 | 0.088 |
Data given as mean±SD or numbers (%) unless otherwise mentioned. MSA, minimum stent area; RLA, reference lumen area. Other abbreviations as in Table 3.